Completed Cystic Fibrosis trials in Ireland

Showing 1 to 25 of 37. Each trial links to its page on Pharma Observatory.

• A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation NCT05076149·Phase 3·Completed·Vertex Pharmaceuticals Incorporated·Started 2021
• A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF) NCT05033080·Phase 3·Completed·Vertex Pharmaceuticals Incorporated·Started 2021
• Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA TC Combination Therapy in Participants With Cystic Fibrosis Who Are 6 Years of Age and Older NCT04183790·Phase 3·Completed·Vertex Pharmaceuticals Incorporated·Started 2020
• Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy NCT04058366·Phase 3·Completed·Vertex Pharmaceuticals Incorporated·Started 2019
• A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F/G and F/RF Genotypes) NCT04058353·Phase 3·Completed·Vertex Pharmaceuticals Incorporated·Started 2019
• A Study Evaluating the Long-term Safety of VX-445 Combination Therapy NCT04043806·Phase 3·Completed·Vertex Pharmaceuticals Incorporated·Started 2019
• A Phase 2 Study to Evaluate Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis NCT03911713·Phase 2·Completed·Vertex Pharmaceuticals Incorporated·Started 2019
• Evaluation of VX 445/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age NCT03691779·Phase 3·Completed·Vertex Pharmaceuticals Incorporated·Started 2018
• Steps Ahead: Optimising Physical Activity and Health in Adults With Cystic Fibrosis NCT03672058·Not applicable·Completed·University of Limerick·Started 2018
• A Study to Evaluate Efficacy and Safety of TEZ/IVA in Subjects Aged 6 Through 11 Years With Cystic Fibrosis NCT03559062·Phase 3·Completed·Vertex Pharmaceuticals Incorporated·Started 2018
• A Study of VX-659 Combination Therapy in CF Subjects Homozygous for F508del (F/F) NCT03460990·Phase 3·Completed·Vertex Pharmaceuticals Incorporated·Started 2018
• A Study to Evaluate the Safety and Efficacy of Long-term Treatment With TEZ/IVA in CF Participants With an F508del CFTR Mutation NCT03537651·Phase 3·Completed·Vertex Pharmaceuticals Incorporated·Started 2018
• A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF) NCT03447249·Phase 3·Completed·Vertex Pharmaceuticals Incorporated·Started 2018
• A Study to Evaluate the Safety of Long-term Ivacaftor Treatment in Participants With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have an Approved Ivacaftor-Responsive Mutation NCT03277196·Phase 3·Completed·Vertex Pharmaceuticals Incorporated·Started 2017
• A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis NCT03224351·Phase 2·Completed·Vertex Pharmaceuticals Incorporated·Started 2017
• A Study to Evaluate GLPG2222 in Ivacaftor-treated Subjects With Cystic Fibrosis NCT03045523·Phase 2·Completed·Lakefront Biotherapeutics NV·Started 2017
• A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age and Have an Ivacaftor-Responsive CFTR Mutation NCT02725567·Phase 3·Completed·Vertex Pharmaceuticals Incorporated·Started 2016
• Study of GLPG1837 in Subjects With Cystic Fibrosis (G551D Mutation) NCT02707562·Phase 2·Completed·Lakefront Biotherapeutics NV·Started 2016
• A Study to Evaluate the Safety and Efficacy of VX-371 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation NCT02709109·Phase 2·Completed·Parion Sciences·Started 2016
• A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Participants With Cystic Fibrosis Who Have an F508del-CFTR Mutation NCT02565914·Phase 3·Completed·Vertex Pharmaceuticals Incorporated·Started 2015
• A Phase 3 Study of Tezacaftor (VX-661) in Combination With Ivacaftor (VX-770) in Subjects Aged 12 Years and Older With Cystic Fibrosis (CF), Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to Ivacaftor NCT02412111·Phase 3·Completed·Vertex Pharmaceuticals Incorporated·Started 2015
• A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor NCT02347657·Phase 3·Completed·Vertex Pharmaceuticals Incorporated·Started 2015
• A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis NCT01931839·Phase 3·Completed·Vertex Pharmaceuticals Incorporated·Started 2013
• Cystic Fibrosis Microbiome-determined Antibiotic Therapy Trial in Exacerbations: Results Stratified NCT02526004·Not applicable·Completed·University College Cork·Started 2013
• Ease of Use and Microbial Contamination of Tobramycin Inhalation Powder (TIP) Versus Nebulised Tobramycin Inhalation Solution (TIS) and Nebulised Colistimethate (COLI) NCT01844778·Phase 4·Completed·Novartis Pharmaceuticals·Started 2013